Based on the available data and the recent FDA approval, the panel consensus was to include nivolumab as a subsequent systemic therapy for locally advanced or metastatic disease. Nivolumab was added as a category 2A option for the following settings:

- Bladder Cancer
- Upper GU Tract Tumors: Renal Pelvis
- Upper GU Tract Tumors: Urothelial carcinoma of the ureter
- Urothelial Carcinoma of the Prostate
- Primary Carcinoma of the Urethra (urothelial carcinomas only)